## **Synthesis of the Ezomycin Nucleoside Disaccharide**

## **Spencer Knapp\* and Vijay K. Gore**

*Department of Chemistry, Rutgers-The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854-8087*

*knapp@rutchem.rutgers.edu*

**Received February 19, 2000**

## **ORGANIC LETTERS 2000 Vol. 2, No. 10 <sup>1391</sup>**-**<sup>1393</sup>**

**ABSTRACT**



**A protected ezomycin octosyl nucleoside was glycosylated at O-6**′ **with a protected ezoaminuroic acid donor to afford, following several** functional group modifications, the title compound  $1 (= 4$ -desamino-4-oxoezomycin  $A_2$ ).

The ezomycins are a class of fermentation-derived complex nucleoside antibiotics<sup>1</sup> whose structures were elucidated in the  $1970s^{2,3}$  They feature an unusual combination of parts: an octosyl nucleoside, a  $[1''\rightarrow 6']$ - $\beta$ -glycosylating 3-amino-3,4-dideoxy-D-glucuronic acid ("ezoaminuroic acid"), and an N-linked pseudopeptide (L-cystathionine).

Three ezomycins containing the L-cystathionine component,  $A_1$ ,  $B_1$ , and  $C_1$  (the anomer of  $B_1$  at  $C_1$ ), are active against certain species of phytopathogenic fungi such as *Sclerotinia* and *Botritus*, whereas those lacking this pseudopeptide (e. g.,  $A_2$  and  $B_2$ ) are inactive. Some members (B, C, and D series) bear a C-5 glycosylated *pseudo*-uracil rather than the more usual N-1 linked pyrimidine nucleoside bases.

A number of synthetic routes to the ezoaminuroic acid portion have appeared,<sup>4,5</sup> and several groups have synthesized

octosyl nucleosides that resemble the ezomycin component.6,7 A method for glycosylating a model octose at C-6′ was reported from our lab in 1994.<sup>5</sup> In this paper we describe the first synthesis of the ezomycin nucleoside disaccharide **1** ( $\equiv$  4-desamino-4-oxoezomycin A<sub>2</sub>).

Although we had previously developed a satisfactory route to the ezoaminuroic acid donor **6**, <sup>5</sup> the requirement of excess donor for the nucleoside glycosylation, and the difficulties associated with large-scale preparation of the Cerny epoxide precursor, prompted us to develop the shorter alternative route shown in Scheme 1. Selective hydrolysis<sup>8</sup> of 3-azido-3-deoxy-1,2:5,6-di-*O*-isopropylidene-R-D-glucofuranose **<sup>2</sup>**, 9

(8) Redlich, H.; Roy, W. *Liebigs Ann. Chem.* **<sup>1981</sup>**, 1223-1233. (9) Meyer zu Reckendorf, W. *Chem. Ber.* **<sup>1968</sup>**, *<sup>101</sup>*, 3802-3807.

<sup>(1)</sup> Recent reviews: Knapp, S. *Chem. Re*V*.* **<sup>1995</sup>**, *<sup>95</sup>*, 1859-1876. Isono, K. *Pharmacol. Ther.* **<sup>1991</sup>**, *<sup>52</sup>*, 269-286.

<sup>(2)</sup> Isolation and biological activity: Sakata, K.; Sakurai, A.; Tamura, S. *Agric. Biol. Chem.* **<sup>1974</sup>**, *<sup>38</sup>*, 1883-1890. Sakata, K.; Sakurai, A.;

Tamura, S. *Agric. Biol. Chem.* **<sup>1977</sup>**, *<sup>41</sup>*, 2027-2032 and references therein. (3) Structures: Sakata, K.; Sakurai, A.; Tamura, S. *Agric. Biol. Chem.* **<sup>1975</sup>**, *<sup>39</sup>*, 885-892. Sakata, K.; Sakurai, A.; Tamura, S. *Agric. Biol. Chem.*

**<sup>1977</sup>**, 41, 2033–2039 and references therein.<br>(4) Mieczkowski, J.: Zamoiski, A. *Bull, Ac*. (4) Mieczkowski, J.; Zamojski, A. *Bull. Acad. Pol. Sci.* **<sup>1975</sup>**, *<sup>23</sup>*, 581- 583. Ogawa, T.; Akatsu, M.; Matsui, M. *Carbohydr. Res.* **<sup>1975</sup>**, *<sup>44</sup>*, C22- 24. Knapp, S.; Levorse, A. T.; Potenza, J. A. *J. Org. Chem.* **<sup>1988</sup>**, *<sup>53</sup>*, 4773- 4779.

<sup>(5)</sup> Knapp, S.; Jaramillo, C.; Freeman, B. *J. Org. Chem.* **<sup>1994</sup>**, *<sup>59</sup>*, 4800- 4804.

<sup>(6)</sup> Kim, K. S.; Szarek, W. A. *Can. J. Chem.* **<sup>1981</sup>**, *<sup>59</sup>*, 878-887. Bovin, N. V.; Zurabyan, S. E.; Khorlin, A. Y. *Carbohydr. Res.* **<sup>1981</sup>**, *<sup>98</sup>*, 25-35. Hanessian, S.; Dixit, D.; Liak, T. *Pure Appl. Chem.* **<sup>1981</sup>**, *<sup>53</sup>*, 129-148. Kim, K. S.; Szarek, W. A. *Carbohydr. Res.* **<sup>1982</sup>**, *<sup>100</sup>*, 169-176. Danishefsky, S.; Hungate, R. *J. Am. Chem. Soc.* **1986**, *108*, 2486-2489. Hanessian, S.; Kloss, J.; Sugawara, T. *J. Am. Chem. Soc.* **<sup>1986</sup>**, *<sup>108</sup>*, 2758- 2759. Sakanaka, O.; Ohmuri, T.; Kozaki, S.; Suami, S. *Bull. Chem. Soc. Jpn.* **<sup>1987</sup>**, *<sup>60</sup>*, 1057-1062. Danishefsky, S. J.; Hungate, R.; Schulte, G. *J. Am. Chem. Soc.* **<sup>1988</sup>**, *<sup>110</sup>*, 7434-7440. Maier, S.; Preuss, R.; Schmidt, R. R. *Liebigs Ann. Chem.* **<sup>1990</sup>**, 483-489. Haraguchi, K.; Hosoe, M.; Tanaka, H.; Tsuruoka, S.; Kanmuri, K.; Miyasaka, T. *Tetrahedron Lett.* **1998**, *39*,

<sup>5517</sup>-5520. See also refs 1 and 5 and references therein. (7) Knapp, S. Shieh, W.-C.; Jaramillo, C.; Trilles, R. V.; Nandan, S. R.

*J. Org. Chem.* **<sup>1994</sup>**, *<sup>59</sup>*, 946-948.

Stevens, J. D. *Methods Carbohydr. Chem.* **1972**, *6*, 123.



and then selective benzylation at O-6 by way of the 5,6-*O*stannyleneacetal,<sup>10</sup> afforded the mono-benzyl ether 3. Hydrolysis of the second isopropylidene ketal and reformulation of the resulting triol as the pyranose 1,2-ketal **4** was followed by reduction of the azide and protection of the amino as its trifluoroacetyl derivative. Radical deoxygenation<sup>11</sup> at C-4 led to the pyranose **5**. Attempted deoxygenation prior to the reduction of the azido function was unsuccessful owing to the reactivity of azido under the reducing conditions.<sup>12</sup> Hydrolysis of **5** to the diol, *O*-pivaloylation in the nonpolar

solvent benzene,<sup>13</sup> and then exchange of pivaloate for phenylthio at C-1 furnished the donor **6**, identical to that prepared previously.5

The octosyl nucleoside acceptor **10** was constructed from thioglycoside donor **7**<sup>7</sup> by N-1 glycosylation of *O*,*O*′-bis- (trimethylsilyl)uracil under conditions previously developed for this purpose (Scheme 2).<sup>7,13,14</sup> The resulting nucleoside **8** was accompanied by varying amounts of the 5-iodinated product **9**. <sup>14</sup> A more efficient overall glycosylation was obtained by driving the reaction further toward **9** with additional *N*-iodosuccinimide, and **9** proved to be superior in subsequent transformations anyway. The uracil was efficiently N-3-protected by using benzyloxymethyl chloride and BEMP,<sup>15</sup> and then the benzylidene was cleaved with  $HCl$  under reducing conditions<sup>16</sup> to give the required acceptor **10** possessing a free C-6′ hydroxyl.

Glycosylation of **10** with no less than 3.6 equiv of donor **6** gave the nucleoside disaccharide **11** in excellent yield considering the complexity and multisite Lewis basicity<sup>17</sup> of the acceptor. A series of highly selective functional group transformations was then carried out to convert **11** to the target ezomycin nucleoside disaccharide **1**. Clean hydrogenolysis of the C-5 iodide was followed by selective hydrogenolysis of the azido to amino<sup>18</sup> and then protection of the amino as its *N*-benzoylcarbamoyl derivative **12**. Hydrogenolysis of the three benzyl protecting groups exposed primary hydroxyls at C-8′ and C-6′′. These were oxidized under Widlanski conditions<sup>19</sup> to afford dicarboxylic acid 13 (for complete conversion, a followup treatment with sodium chlorite was required). Ammonolysis in methanol solution removed the four acyl protecting groups (indicated by dashed arrows) and provided **1** directly. The nucleoside disaccharide was purified by HPLC and characterized by HRMS and  $COSY$ -assisted  ${}^{1}H$  NMR analysis, which confirmed the full deprotection and the close similarity of **1** to ezomycin  $A<sub>2</sub>$ .





We envision modifying this synthetic route to include conversion of the pyrimidine base from uracil to cytosine and site-selective attachment of the cystathionine to afford ezomycin A<sub>1</sub>.

- (10) Veyrieres, A.; Thieffry, A.; David, S. *J. Chem. Soc., Perkin Trans. <sup>1</sup>* **<sup>1981</sup>**, 1796-1801. (11) Barton, D. H. R.; Ferreira, J. A.; Jaszberenyi, J. C. *Prep. Carbohydr.*
- *Chem.* **<sup>1997</sup>**, 151-172.
- (12) For example, see: Benati, L.; Nanni, D.; Sangiorgi, C.; Spagnolo, P. *J. Org. Chem.* **<sup>1999</sup>**, *<sup>64</sup>*, 7836-7841.
- (13) Knapp, S.; Nandan, S. R. *J. Org. Chem.* **<sup>1994</sup>**, *<sup>59</sup>*, 281-283.
- (14) Knapp, S.; Shieh, W.-C. *Tetrahedron Lett.* **<sup>1991</sup>**, *<sup>32</sup>*, 3627- 3630.
- (15) Schwesinger, R.; Schlemper, H. *Angew. Chem., Int. Ed. Engl.* **1987**, *<sup>26</sup>*, 1167-1169.
- (16) Garegg, P. J.; Hultberg, J.; Wallin, S. *Carbohydr. Res.* **1982**, *108*,  $97 - 101.$
- (17) Knapp, S.; Gore, V. K. *J. Org. Chem.* **<sup>1996</sup>**, *<sup>61</sup>*, 6744-6747 and references therein.

**Acknowledgment.** We thank Hoffmann-La Roche for financial support, Silvano DeBernardo and Theodore Lambros for helpful suggestions for the synthesis of **6** and the purification of **1**, respectively, and Gino Sasso, Vance Bell, Richard Szypula, and Theresa Burchfield of the Physical Chemistry Department at Hoffmann-La Roche for obtaining NMR and mass spectra.

**Supporting Information Available:** Experimental procedures and spectroscopic characterization for new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

## OL005696F

<sup>(18)</sup> Corey, E. J.; Nicolaou, K. C.; Balanson, R. D.; Machida, Y. *Synthesis* **<sup>1975</sup>**, 590-591.

<sup>(19)</sup> Epp, J. B.; Widlanski, T. S. *J. Org. Chem.* **<sup>1999</sup>**, *<sup>64</sup>*, 293-295.